Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2026-03-31 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : Le Rezurock de Sanofi approuvé dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte
Regulatory Filings Classification · 24% confidence The document is a corporate press release (communiqué de presse) announcing the European conditional marketing approval of a pharmaceutical product (Rezurock) by Sanofi. It does not contain financial results, board changes, dividend notices, M&A, share transactions, or other specific regulatory filings like a 10-K, 20-F, or interim report. It is a general regulatory announcement about drug approval and thus best fits the fallback category for miscellaneous regulatory announcements: RNS.
2026-03-31 French
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares
2026-03-30 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares
2026-03-30 French
Communiqué de presse : AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute
Regulatory Filings Classification · 65% confidence The document is a press release (“Communiqué de presse”) by Sanofi summarizing new phase 3 clinical trial results for amlitelimab presented at a medical conference (AAD 2026). It contains detailed clinical data but is not a financial report, investor presentation, regulatory registration document, or management/board announcement. It does not fit any specific filing category such as earnings release, capital raising, share transaction, governance, or ESG report. Therefore, it falls under the fallback category for miscellaneous regulatory announcements.
2026-03-28 French
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing clinical trial results for a biopharma product. It is not an earnings release, regulatory submission, annual or interim financial report, management change announcement, share issuance, M&A, or any other specified category. It does not provide a link to a formal report or constitute the report itself. It therefore falls under the fallback category for miscellaneous corporate/regulatory announcements.
2026-03-28 English
Communiqué de presse : La formulation sous-cutanée de Sarclisa de Sanofi, administrée via un injecteur portable, est recommandée par le CHMP pour approbation dans l'UE dans le traitement du myélome mu
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing a regulatory recommendation by the EMA’s CHMP for Sanofi’s SC formulation of Sarclisa. It does not present financial results, insider transactions, management changes, or detailed investor presentation slides, nor is it an actual clinical study report. It is an official regulatory status update/fallback filing type. Therefore, the correct classification is a general regulatory announcement (RNS).
2026-03-27 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.